There are so many exciting things to look forward to. Ready for some battle royale again? Sword Art Online Alternative: Gun ...

STAAR Surgical (NASDAQ:STAA) rose 6.5% amid some takeover speculation. The maker of implantable lenses is said to have been ...

Six analysts surveyed by Zacks expected $87.2 million. Staar Surgical expects full-year revenue in the range of $340 million to $345 million. This story was generated by Automated Insights (http ...

(Instead of: APAC sales growth of 4% (prior outlook was 7%), including approximately 2% growth in China (prior outlook was 10%). Staar Surgical (STAA) delivered earnings and revenue surprises of ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Greetings and welcome to the STAAR Surgical Third Quarter 2024 Earnings ... to the $8 million or 10% increase in ICL sales and $0.2 million decrease in other products. Constant currency net ...

- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding ...

That's changing with the second generation model. The new Blink Mini 2 is still a compact, affordable camera, but it also ...

*The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. It is possible that this date will be updated in the future, once the company announces ...

Sangamo engaged with the FDA on alternative pathways to potential approval following analysis of clinical data from the Phase 1/2 STAAR study showing encouraging safety and efficacy data ...

STAAR Surgical Company beats earnings expectations ... attributable to the $8 million or 10% increase in ICL sales and $0.2 million decrease in other products. Constant currency net sales for ...